Blueprint Medicines (NASDAQ:BPMC) Research Coverage Started at Morgan Stanley
Morgan Stanley started coverage on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a research note published on Thursday, Marketbeat reports. The brokerage issued an equal weight rating and a $100.00 price objective on the biotechnology company’s stock. Several other analysts also recently issued reports on BPMC. Piper Sandler upped their price target on […]
Morgan Stanley started coverage on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a research note published on Thursday, Marketbeat reports. The brokerage issued an equal weight rating and a $100.00 price objective on the biotechnology company’s stock. Several other analysts also recently issued reports on BPMC. Piper Sandler upped their price target on […]
